Organon (OGN) is a Healthcare company in the Drug Manufacturers General industry. It has a market capitalization of $3.64B, a trailing price-to-earnings ratio of 4.3 and a free-cash-flow yield of 10.6%. Over the most recent reported fiscal year, revenue declined 2.9% and free cash flow per share fell 35.1%. Nama's AI scorecard rates it Sell, 4.1 out of 10. On 12-month momentum it ranks in the rising band of its market.
AI scorecard
Sell · 4.1/10
Negative, at the mild end of Sell. As of Nov 7, 2026.
Momentum
Rising · +105.5% over 12 months ex. last
Second-best fifth of its market on the past year's move.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-64.9%
How far the last close sits under the highest price of the past five years.
Market cap
$3.64B
Trailing P/E
4.3
Price / book
3.6
Price / sales
0.6
FCF yield
10.6%
Dividend yield
0.6%
Gross margin
52.7%
Operating margin
19.0%
Net margin
3.4%
Revenue growth (YoY)
-2.9%
Revenue growth (3-yr annual)
+0.2%
EPS growth (YoY)
-10.9%
FCF/share growth (YoY)
-35.1%
Beta
1.5
Exchange
NYSE
Sector
Healthcare
Industry
Drug Manufacturers General
OGN earnings
Next report: Nov 9, 2026 (Q3 2026, EPS estimate $0.95).
Beat the EPS estimate in 1 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q2 2026
Jul 31, 2026
$0.85
$1.07
-20.6%
$1.56B
Q1 2026
Apr 30, 2026
$0.71
$0.85
-16.5%
$1.46B
Q4 2025
Feb 12, 2026
$0.63
$0.73
-13.7%
$1.51B
Q3 2025
Nov 10, 2025
$1.01
$0.93
+8.6%
$1.60B
OGN analyst price target
Median target $9.00 from 3 analysts, ranging $8.00 – $14.00.
Nama's AI scorecard currently rates Organon Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is OGN's P/E ratio?
Organon trades at a trailing price-to-earnings ratio of 4.3.
When does OGN report earnings?
Organon's next scheduled report is on Nov 9, 2026. Analysts expect EPS of $0.95.
What is the OGN price target?
The median analyst price target from 3 analysts is $9.00, with a range of $8.00 – $14.00.
Is OGN Shariah compliant?
Nama's AAOIFI-style screen reads Organon as Not Shariah Compliant. At least one of the three ratios or the industry test failed.